A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency - Contacts and Locations

A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency

This study has been completed.

Study NCT00389324. Last updated on September 12, 2008. Information provided by Talecris Biotherapeutics

Please refer to this study by its ClinicalTrials.gov identifier: NCT00389324

Locations


United States, California
	UCLA School of Medicine
	Los Angeles, California, United States, 90095
	University of California, Irvine
	Irvine, California, United States, 92697

United States, Georgia
	Family Allergy & Asthma Center, PC
	Atlanta, Georgia, United States, 30342

United States, Nebraska
	Allergy, Asthma & Immunology Associates, PC
	Omaha, Nebraska, United States, 68124

United States, Texas
	Pediatric Allergy / Immunology Associates, PA
	Dallas, Texas, United States, 75230

United States, Virginia
	Virginia Commonwealth University
	Richmond, Virginia, United States, 23219

Canada, British Columbia
	Dr. Donald F. Stark, Inc
	Vancouver, British Columbia, Canada, V6H3K2

Canada, Quebec
	McGill University - Montreal General Hospital
	Montreal, Quebec, Canada, H3G1A4

Sponsors and Collaborators

Talecris Biotherapeutics

Investigators


Study Director:	Susan Sorrells	Talecris Biotherapeutics